Sugi Predict

Sugi Predict / Compounds / SCHEMBL4665082

SCHEMBL4665082

SCHEMBL4665082

CC(Cc1ccc(OCc2ccccc2)cc1)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 2/20 0.67
▸ PPARA Q07869 4/20 0.65
▸ PPARG P37231 4/20 0.65
▸ MAOB P27338 2/20 0.63
▸ PPARD Q03181 1/20 0.61
▸ FFAR4 Q5NUL3 1/20 0.60
▸ LTA4H P09960 2/20 0.58
▸ MME P08473 1/20 0.57
▸ ACE P12821 1/20 0.57
▸ CPA1 P15085 1/20 0.57
▸ ACE2 Q9BYF1 1/20 0.57
▸ LAP3 P28838 1/20 0.57
▸ NR4A1 P22736 1/20 0.57
▸ NR4A2 P43354 1/20 0.57
▸ NR4A3 Q92570 1/20 0.57
▸ ALOX5 P09917 3/20 0.56
▸ LMNA P02545 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ PTGS1 P23219 1/20 0.55
▸ PTGS2 P35354 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10071090 1.00 FFAR1 (0.67) FFAR1PPARAPPARGMAOBPPARD
SCHEMBL14501342 0.89 MAOB (0.61) FFAR1PPARAPPARGMAOBPPARD
SCHEMBL14501338 0.89 MAOB (0.61) FFAR1PPARAPPARGMAOBPPARD
SCHEMBL25901508 0.88 LTA4H (0.65) FFAR1PPARAPPARGMAOBPPARD
SCHEMBL11445970 0.88 MAOB (0.60) FFAR1PPARAPPARGMAOBPPARD
SCHEMBL21366441 0.87 LTA4H (0.68) FFAR1PPARAPPARGMAOBPPARD
SCHEMBL27977003 0.87 LTA4H (0.68) FFAR1PPARAPPARGMAOBPPARD
SCHEMBL8416496 0.87 MAOB (0.59) FFAR1PPARAPPARGMAOBPPARD
SCHEMBL7801265 0.85 PPARA (0.70) FFAR1PPARAPPARGMAOBPPARD
SCHEMBL6029226 0.85 FFAR1 (0.67) FFAR1MAOBFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771543-B2 Poly(ester urea) adhesion barriers for use in the treatment of hernia-mesh repair THE UNIVERSITY OF AKRON (US) 2023-10-03 — — US disclosed
US-9988492-B2 Methods for post-fabrication functionalization of poly(ester ureas) THE UNIVERSITY OF AKRON (US) 2018-06-05 — — US disclosed
US-20160237212-A1 METHODS FOR POST-FABRICATION FUNCTIONALIZATION OF POLY(ESTER UREAS) THE UNIVERSITY OF AKRON (US) 2016-08-18 — — US disclosed
US-20110319362-A1 STAT3 LIGANDS AND THERAPEUTIC USES THEREOF WANG SHAOMENG (US) 2011-12-29 — — US disclosed
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS GODEL THIERRY 2008-06-05 — — US disclosed
CN-1886391-A Teramic acid and threonine as beta-secretase inhibitors HOFFMANN LA ROCHE (CH) 2006-12-27 — — CN disclosed
EP-1689729-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. Hoffmann-La Roche AG (CH) 2006-08-16 — — EP disclosed
WO-2005058857-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 — — WO disclosed
WO-2005058857-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 — — WO disclosed
US-20050119329-A1 Tetronic and tetramic acids HOFFMANN-LA ROCHE INC. 2005-06-02 — — US disclosed
EP-0449175-B1 Selective adenosine receptor agents MERRELL PHARMA INC (US) 1997-07-30 — — EP disclosed
CN-1118599-A Xanthine derivatives as adenosine A1 receptor antagonists MERRELL DOW PHARMA (US) 1996-03-13 — — CN disclosed
EP-0686155-A1 XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS MERRELL PHARMACEUTICALS INC. (US) 1995-12-13 — — EP disclosed
WO-1994019349-A1 XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS MERRELL DOW PHARMACEUTICALS INC. (US) 1994-09-01 — — WO disclosed
US-5208240-A Alzeheimer's, cardiovascular, respiratory MERRELL DOW PHARMACEUTICALS INC. (US) 1993-05-04 — — US disclosed
EP-0503563-A2 Novel 8-substituted purines as selective adenosine receptor agents MERRELL PHARMACEUTICALS INC. (US) 1992-09-16 — — EP disclosed
EP-0449175-A2 Selective adenosine receptor agents MERRELL PHARMACEUTICALS INC. (US) 1991-10-02 — — EP disclosed
US-5047534-A Xanthine derivatives; hyupotensive agents, cardiotonic agents MERRELL DOW PHARMACEUTICALS INC. (US) 1991-09-10 — — US disclosed
EP-0009683-A1 Basic phenyl ethers, pharmaceutical compositions containing them and the preparation of these ethers and compositions MERCK PATENT GmbH (DE) 1980-04-16 — — EP disclosed
US-4080471-A ANTIARRYTHMIA AKTIEBOLAGET HASSLE (SW) 1978-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237212-A1 METHODS FOR POST-FABRICATION FUNCTIONALIZATION OF POLY(ESTER UREAS) PTMS, MUSK, DSTYK FFAR1 2468/4885PPARA 2232/4885PPARG 3808/4885
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS BACE1, PSEN1, BACE2 FFAR1 601/4885PPARA 2704/4885PPARG 3310/4885
US-20050119329-A1 Tetronic and tetramic acids BACE1, PSEN1, BACE2 FFAR1 601/4885PPARA 2704/4885PPARG 3310/4885
US-20110319362-A1 STAT3 LIGANDS AND THERAPEUTIC USES THEREOF STAT3, JAK2, STAT6 FFAR1 4119/4885PPARA 985/4885PPARG 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.